Načítá se...
Update on the safety and efficacy of teriparatide in the treatment of osteoporosis
Following the completion of the Fracture Prevention Trial, teriparatide was approved by the United States Food and Drug Administration and the European Medicine Agency as the first therapeutic anabolic agent for the treatment of postmenopausal women with severe osteoporosis. It subsequently received...
Uloženo v:
| Vydáno v: | Ther Adv Musculoskelet Dis |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6778993/ https://ncbi.nlm.nih.gov/pubmed/31632472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X19877994 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|